|
1
|
Dorfman HD and Czerniak B: Bone cancers.
Cancer. 75 (1 Suppl):S203–S210. 1995. View Article : Google Scholar
|
|
2
|
Fujiwara T and Ozaki T: Overcoming
therapeutic resistance of bone sarcomas: Overview of the molecular
mechanisms and therapeutic targets for bone sarcoma stem cells.
Stem Cells Int. 2016:26030922016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galoian K, Qureshi A, D'Ippolito G,
Schiller PC, Molinari M, Johnstone AL, Brothers SP, Paz AC and
Temple HT: Epigenetic regulation of embryonic stem cell marker
miR302C in human chondrosarcoma as determinant of antiproliferative
activity of proline-rich polypeptide 1. Int J Oncol. 47:465–472.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galoian K, Abrahamyan S, Chailyan G,
Qureshi A, Patel P, Metser G, Moran A, Sahakyan I, Tumasyan N, Lee
A, et al: Toll like receptors TLR1/2, TLR6 and MUC5B as binding
interaction partners with cytostatic proline rich polypeptide 1 in
human chondrosarcoma. Int J Oncol. 52:139–154. 2018.PubMed/NCBI
|
|
5
|
Vermeulen L, Todaro M, de Sousa Mello F,
Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G and Medema
JP: Single-cell cloning of colon cancer stem cells reveals a
multi-lineage differentiation capacity. Proc Natl Acad Sci USA.
105:13427–13432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sell S: On the stem cell origin of cancer.
Am J Pathol. 176:2584–2494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Honoki K, Fujii H, Kubo A, Kido A, Mori T,
Tanaka Y and Tsujiuchi T: Possible involvement of stem-like
populations with elevated ALDH1 in sarcomas for chemotherapeutic
drug resistance. Oncol Rep. 24:501–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanei T, Morimoto K, Shimazu K, Kim SJ,
Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast
cancer stem cells identified by aldehyde dehydrogenase 1 expression
with resistance to sequential paclitaxel and epirubicin-based
chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Awad O, Yustein JT, Shah P, Gul N, Katuri
V, O'Neill A, Kong Y, Brown ML, Toretsky JA and Loeb DM: High ALDH
activity identifies chemotherapy-resistant Ewing's sarcoma stem
cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One.
5:e139432010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galoyan A: Neurochemistry of brain
neuroendocrine immune system: Signal molecules. Neurochem Res.
25:1343–1355. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Galoian K, Temple TH and Galoyan A:
Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by
mTOR and cMyc inhibition in high grade chondrosarcoma. Neurochem
Res. 36:812–818. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Galoian K, Qureshi A, Wideroff G and
Temple HT: Restoration of desmosomal junction protein expression
and inhibition of H3K9-specific histone demethylase activity by
cytostatic proline-rich polypeptide-1 leads to suppression of
tumorigenic potential in human chondrosarcoma cells. Mol Clin
Oncol. 3:171–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Galoian K, Luo S, Qureshi A, Patel P,
Price R, Morse AS, Chailyan G, Abrahamyan S and Temple HT: Effect
of cytostatic proline rich polypeptide-1 on tumor suppressors of
inflammation pathway signaling in chondrosarcoma. Mol Clin Oncol.
5:618–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Galoian KA, Guettouche T, Issac B, Qureshi
A and Temple HT: Regulation of onco and tumor suppressor MiRNAs by
mTORC1 inhibitor PRP-1 in human chondrosarcoma. Tumour Biol.
35:2335–2341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galoian KA, Temple TH and Galoyan A:
Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA
231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal
tumors. Tumour Biol. 32:745–751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lohberger B, Rinner B, Stuendl N, Absenger
M, Liegl- Atzwanger B, Walzer SM, Windhager R and Leithner A:
Aldehyde dehydrogenase 1, a potential marker for cancer stem cells
in human sarcoma. PLoS One. 7:e436642012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakahata K, Uehara S, Nishikawa S, Kawatsu
M, Zenitani M, Oue T and Okuyama H: Aldehyde dehydrogenase 1
(ALDH1) is a potential marker for cancer stem cells in embryonal
rhabdomyosarcoma. PLoS One. 10:e01254542015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tolstorukov MY, Sansam CG, Lu P,
Koellhoffer EC, Helming KC, Alver BH, Tillman EJ, Evans JA, Wilson
BG, Park PJ and Roberts CW: Swi/Snf chromatin remodeling/tumor
suppressor complex establishes nucleosome occupancy at target
promoters. Proc Natl Acad Sci USA. 110:10165–10170. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ueda K, Ogasawara S, Akiba J, Nakayama M,
Todoroki K, Ueda K, Sanada S, Suekane S, Noguchi M, Matsuoka K and
Yano H: Aldehyde dehydrogenase 1 identifies cells with cancer stem
cell-like properties in a human renal cell carcinoma cell line.
PLoS One. 8:e754632013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hoyt AK, Moran A, Granger C, Sedani A,
Saigh S, Brown J and Galoian KA: PRP1 significantly decreases the
ALDHhigh cancer stem cell population and regulates the aberrant
Wnt/β-catenin pathway in human chondrosarcoma JJ012 cells. Oncol
Rep. 42:103–114. 2019.PubMed/NCBI
|
|
22
|
Kim WT and Ryu CJ: Cancer stem cell
surface markers on normal stem cells. BMB Rep. 50:285–298. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wirths S, Malenke E, Kluba T, Rieger S,
Müller MR, Schleicher S, Hann von Weyhern C, Nagl F, Fend F, Vogel
W, et al: Shared cell surface marker expression in mesenchymal stem
cells and adult sarcomas. Stem Cells Transl Med. 2:53–60. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Genadry KC, Pietrobono S, Rota R and
Linardic CM: Soft tissue sarcoma cancer stem cells: An overview.
Front Oncol. 8:4752018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mak AB, Pehar M, Nixon AM, Williams RA,
Uetrecht AC, Puglielli L and Moffat J: Post-translational
regulation of CD133 by ATase1/ATase2-mediated lysine acetylation. J
Mol Biol. 426:2175–2182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jacques C, Lamoureux F, Baud'huin M,
Rodriguez Calleja L, Quillard T, Amiaud J, Tirode F, Rédini F,
Bradner JE, Heymann D and Ory B: Targeting the epigenetic readers
in Ewing sarcoma inhibits the oncogenic transcription factor
EWS/Fli1. Oncotarget. 7:24125–24140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang JC: Cellular roles of DNA
topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol.
3:430–440. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pulleyblank DE: Of topo and maxwell's
dream. Science. 277:648–649. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li TK and Liu LF: Tumor cell death induced
by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol.
41:53–77. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
da Cunha IW, De Brot L, Carvalho KC, Rocha
RM, Fregnani JH, Falzoni R, Ferreira Fde O, Aguiar S Jr, Lopes A,
Muto NH, et al: Prognostication of soft tissue sarcomas based on
chromosome 17q gene and protein status: Evaluation of TOP2A,
HER-2/neu, and survivin. Ann Surg Oncol. 19:1790–1799. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baiocchi G, Poliseli FL, De Brot L,
Mantoan H, Schiavon BN, Faloppa CC, Vassallo J, Soares FA and Cunha
IW: TOP2A copy number and TOP2A expression in uterine benign smooth
muscle tumours and leiomyosarcoma. J Clin Pathol. 69:884–889. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Raab JR, Runge JS, Spear CC and Magnuson
T: Co-regulation of transcription by BRG1 and BRM, two mutually
exclusive SWI/SNF ATPase subunits. Epigenetics Chromatin.
10:622017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Douglas D, Hsu JH, Hung L, Cooper A,
Abdueva D, van Doorninck J, Peng G, Shimada H, Triche TJ and Lawlor
ER: BMI-1 promotes ewing sarcoma tumorigenicity independent of
CDKN2A repression. Cancer Res. 68:6507–6515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pietersen AM, Horlings HM, Hauptmann M,
Langerød A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers
J, van de Vijver MJ and van Lohuizen M: EZH2 and BMI1 inversely
correlate with prognosis and TP53 mutation in breast cancer. Breast
Cancer Res. 10:R1092008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dhawan S, Tschen SI and Bhushan A: Bmi-1
regulates the Ink4a/Arf locus to control pancreatic beta-cell
proliferation. Genes Dev. 23:906–911. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Becker M, Korn C, Sienerth AR, Voswinckel
R, Luetkenhaus K, Ceteci F and Rapp UR: Polycomb group protein Bmi1
is required for growth of RAF driven non-small-cell lung cancer.
PLoS One. 4:e42302009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dovey JS, Zacharek SJ, Kim CF and Lees JA:
Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem
cell expansion. Proc Natl Acad Sci USA. 105:11857–11862. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bruggeman SW, Hulsman D, Tanger E, Buckle
T, Blom M, Zevenhoven J, van Tellingen O and van Lohuizen M: Bmi1
controls tumor development in an Ink4a/Arf-independent manner in a
mouse model for glioma. Cancer Cell. 12:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang E, Bhattacharyya S, Szabolcs A,
Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P,
Sood AK and Bhattacharya R: Enhancing chemotherapy response with
Bmi-1 silencing in ovarian cancer. PLoS One. 6:e179182011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsu JH and Lawlor ER: BMI 1 suppresses
contact inhibition and stabilizes YAP in Ewing sarcoma. Oncogene.
30:2077–2085. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu Z, Min L, Chen D, Hao D, Duan Y, Qiu G
and Wang Y: Overexpression of BMI-1 promotes cell growth and
resistance to cisplatin treatment in osteosarcoma. PLoS One.
6:e146482011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu L, Andrews LG and Tollefsbol TO: Loss
of the human polycomb group protein BMI1 promotes cancer-specific
cell death. Oncogene. 25:4370–4375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bracken AP, Kleine-Kohlbrecher D, Dietrich
N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Mönch K, Minucci S,
Porse BT, Marine JC, et al: The Polycomb group proteins bind
throughout the INK4A-ARF locus and are disassociated in senescent
cells. Genes Dev. 21:525–530. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu W, Stein P, Cheng X, Yang W, Shao NY,
Morrisey EE, Schultz RM and You J: BRD4 regulates Nanog expression
in mouse embryonic stem cells and preimplantation embryos. Cell
Death Differ. 21:1950–1960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gonzales-Cope M, Sidoli S, Bhanu NV, Won
KJ and Garcia BA: Histone H4 acetylation and the epigenetic reader
Brd4 are critical regulators of pluripotency in embryonic stem
cells. BMC Genomics. 17:952016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rahnamoun H, Lee J, Sun Z, Lu H, Ramsey
KM, Komives EA and Lauberth SM: RNAs interact with BRD4 to promote
enhanced chromatin engagement and transcription activation. Nat
Struct Mol Biol. 25:687–697. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang HT, Gui T, Sang Y, Yang J, Li YH,
Liang GH, Li T, He QY and Zha ZG: The BET bromodomain inhibitor JQ1
suppresses chondrosarcoma cell growth via regulation of
YAP/p21/c-Myc signaling. J Cell Biochem. 118:2182–2192. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
McBride MJ and Kadoch C: Disruption of
mammalian SWI/SNF and polycomb complexes in human sarcomas:
Mechanisms and therapeutic opportunities. J Pathol. 244:638–649.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
De-Meng Chen X-QZ, Kai Wang and Yi-Zhou
Jiang: SWI/SNF chromatin remodeling complex in regulating
mesenchymal stem cell lineage specification. J Tissue Sci
Engineering. 6:1542015.
|
|
50
|
Yang J, Ren Z, Du X, Hao M and Zhou W: The
role of mesenchymal stem/progenitor cells in sarcoma: Update and
dispute. Stem Cell Investig. 1:182014.PubMed/NCBI
|
|
51
|
Tang L, Nogales E and Ciferri C: Structure
and function of SWI/SNF chromatin remodeling complexes and
mechanistic implications for transcription. Prog Biophys Mol Biol.
102:122–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wilson BG, Wang X, Shen X, McKenna ES,
Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH and
Roberts CW: Epigenetic antagonism between polycomb and SWI/SNF
complexes during oncogenic transformation. Cancer Cell. 18:316–328.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
de Andrea CE and Hogendoorn PC: Epiphyseal
growth plate and secondary peripheral chondrosarcoma: The
neighbours matter. J Pathol. 226:219–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kadoch C, Williams RT, Calarco JP, Miller
EL, Weber CM, Braun SM, Pulice JL, Chory EJ and Crabtree GR:
Dynamics of BAF-Polycomb complex opposition on heterochromatin in
normal and oncogenic states. Nat Genet. 49:213–222. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shao Z, Raible F, Mollaaghababa R, Guyon
JR, Wu CT, Bender W and Kingston RE: Stabilization of chromatin
structure by PRC1, a Polycomb complex. Cell. 98:37–46. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Poynter ST and Kadoch C: Polycomb and
trithorax opposition in development and disease. Wiley Interdiscip
Rev Dev Biol. 5:659–688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang X, Li B, Li W, Ma L, Zheng D, Li L,
Yang W, Chu M, Chen W, Mailman RB, et al: Transcriptional
repression by the BRG1-SWI/SNF complex affects the pluripotency of
human embryonic stem cells. Stem Cell Reports. 3:460–474. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kahali B, Yu J, Marquez SB, Thompson KW,
Liang SY, Lu L and Reisman D: The silencing of the SWI/SNF subunit
and anticancer gene BRM in Rhabdoid tumors. Oncotarget.
5:3316–3332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fulda S and Kogel D: Cell death by
autophagy: Emerging molecular mechanisms and implications for
cancer therapy. Oncogene. 34:5105–5113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kanzawa T, Germano IM, Komata T, Ito H,
Kondo Y and Kondo S: Role of autophagy in temozolomide-induced
cytotoxicity for malignant glioma cells. Cell Death Differ.
11:448–457. 2004. View Article : Google Scholar : PubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBI
|
